Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabetes Patients Not Using Insulin Over 26 Weeks

Loading news article.

Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabetes Patients Not Using Insulin Over 26 Weeks | WAPE

Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabetes Patients Not Using Insulin Over 26 Weeks

Article summary

Related companies

Comments —